Date Filed | Type | Description |
10/10/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
08/14/2023 |
SC 13D
| Astellas US LLC reports a 8.7% stake in POSEIDA THERAPEUTICS, INC. |
08/11/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/08/2023 |
8-K
| Quarterly results |
08/07/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, ... |
06/16/2023 |
4
| Collins Cynthia (Director) has filed a Form 4 on Poseida Therapeutics, Inc.
Txns:
| Granted 19,650 shares
@ $0 Granted 27,350 options to buy
@ $2.47, valued at
$67.6k
|
|
06/16/2023 |
4
| Schmid John P. (Director) has filed a Form 4 on Poseida Therapeutics, Inc.
Txns:
| Granted 19,650 shares
@ $0 Granted 27,350 options to buy
@ $2.47, valued at
$67.6k
|
|
06/16/2023 |
4
| Lloyd Marcea Bland (Director) has filed a Form 4 on Poseida Therapeutics, Inc.
Txns:
| Granted 19,650 shares
@ $0 Granted 27,350 options to buy
@ $2.47, valued at
$67.6k
|
|
06/16/2023 |
4
| BAUM CHARLES M (Director) has filed a Form 4 on Poseida Therapeutics, Inc.
Txns:
| Granted 19,650 shares
@ $0 Granted 27,350 options to buy
@ $2.47, valued at
$67.6k
|
|
06/16/2023 |
4
| Corning Luke (Director) has filed a Form 4 on Poseida Therapeutics, Inc.
Txns:
| Granted 19,650 shares
@ $0 Granted 27,350 options to buy
@ $2.47, valued at
$67.6k
|
|
06/16/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
06/01/2023 |
8-K
| Termination of a Material Definitive Agreement, Other Events Interactive Data |
05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
05/09/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
05/02/2023 |
4
| Amado Rafael (Director) has filed a Form 4 on Poseida Therapeutics, Inc.
Txns:
| Granted 39,300 shares
@ $0 Granted 55,200 options to buy
@ $2.76, valued at
$152.4k
|
|
04/26/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
04/26/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
04/26/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
04/14/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
03/09/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
03/09/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
03/02/2023 |
4
| Warner Brent (President, Gene Therapy) has filed a Form 4 on Poseida Therapeutics, Inc.
Txns:
| Granted 92,772 shares
@ $0 Paid exercise price by delivering 26,617 shares
@ $5.35, valued at
$142.4k
Granted 125,283 options to buy
@ $5.35, valued at
$670.3k
|
|
03/02/2023 |
4
| Mylet Johanna (CFO) has filed a Form 4 on Poseida Therapeutics, Inc.
Txns:
| Granted 92,772 shares
@ $0 Paid exercise price by delivering 4,323 shares
@ $5.35, valued at
$23.1k
Granted 125,283 options to buy
@ $5.35, valued at
$670.3k
|
|
03/02/2023 |
4
| LEONHARDT HARRY J (GC & Chief Compliance Officer) has filed a Form 4 on Poseida Therapeutics, Inc.
Txns:
| Granted 92,772 shares
@ $0 Paid exercise price by delivering 4,323 shares
@ $5.35, valued at
$23.1k
Granted 125,283 options to buy
@ $5.35, valued at
$670.3k
|
|
03/02/2023 |
4
| Gergen Mark J (President and CEO) has filed a Form 4 on Poseida Therapeutics, Inc.
Txns:
| Granted 269,586 shares
@ $0 Granted 364,060 options to buy
@ $5.35, valued at
$1.9M
|
|
02/22/2023 |
8-K
| Quarterly results |
02/09/2023 |
SC 13G/A
| FMR LLC reports a 15% stake in POSEIDA THERAPEUTICS INC |
02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/31/2023 |
8-K
| Quarterly results |
01/17/2023 |
5
| Form 5 - Annual statement of changes in beneficial ownership of securities: |
01/12/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
12/06/2022 |
8-K
| Quarterly results |
|